Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Health policy

Affordability of drugs used in oncology health care

Nature Reviews Clinical Oncology volume 13, pages 331–332 (2016)Cite this article

Subjects

The rapidly rising costs of cancer care, driven in particular by the high prices of new drugs, are increasingly challenging health-care systems across the world. To ensure accessibility to novel antitumour drugs, novel paradigms are needed at several levels, not only economically, but also in terms of research and new study designs.

Refers to van Eijsden, P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 351, h6778 (2015)

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Eijsden, P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 351, h6778 (2015).

    Article  Google Scholar 

  2. van Harten, W. H., Wind, A., de Paoli, P., Saghatchian, M. & Oberst, S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 17, 18–20 (2016).

    Article  Google Scholar 

  3. Beije, N., Jager, A. & Sleijfer, S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat. Rev. 41, 144–150 (2015).

    Article  Google Scholar 

  4. Sickinger, M. T. et al. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst. Rev. 1, CD010533 (2015).

    PubMed  Google Scholar 

  5. Davar, D., Socinski, M. A., Dacic, S. & Burns, T. F. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp. Hematol. Oncol. 4, 34 (2015).

    Article  Google Scholar 

  6. Sleijfer, S., Bogaerts, J. & Siu, L. L. Designing transformative clinical trials in the cancer genome era. J. Clin. Oncol. 31, 1834–1841 (2013).

    Article  Google Scholar 

  7. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Stefan Sleijfer is at the Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands.

    Stefan Sleijfer

  2. Jaap Verweij is at the Faculty of Medicine and Health Sciences, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam, Netherlands.

    Jaap Verweij

Authors
  1. Stefan Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaap Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaap Verweij.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Hartwig Medical Foundation

CPCT

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sleijfer, S., Verweij, J. Affordability of drugs used in oncology health care. Nat Rev Clin Oncol 13, 331–332 (2016). https://doi.org/10.1038/nrclinonc.2016.77

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.77

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing